Biomedical Advanced Research and Development Authority (BARDA)
330 C Street, SW
Room G640
Washington
D.C.
20201
United States
Tel: 202-260-1200
Fax: 202-205-4520
171 articles with Biomedical Advanced Research and Development Authority (BARDA)
-
An ugly symbol of racism appears to have reared its head at a Merck facility in North Carolina. The pharma giant is investigating reports of a noose found hanging at a construction project on the 262-acre facility.
-
MediciNova Initiates Sheep Study under Partnership with BARDA to Develop MN-166 (ibudilast) as a Medical Countermeasure Against Chlorine Gas-induced Lung Injury
6/7/2021
MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market and the JASDAQ Market of the Tokyo Stock Exchange, announced it has initiated a sheep study to investigate MN-166 in an ovine model of chlorine-induced acute lung injury.
-
The nation’s top science adviser believes the country’s renewed enthusiasm for science may pave the way for plug-and-play vaccines that can nullify the next pandemic before it starts.
-
A two-stage Phase III clinical trial by Sanofi and GSK, is studying a COVID-19 vaccine candidate targeting the original SARS-CoV-2 strain as well as the South African B.1.351 variant.
-
Sepsis is among the best-known and least effectively treated conditions in the modern world. The standard of care has failed for these infections, leaving the U.S. healthcare system with $62 billion and 270,000 deaths annually. Globally, 11 million die from sepsis each year. Effective drugs and d...
-
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for March 23, 2021.
-
AMRI Included in BARDA CDMO Network in Support of COVID-19 Pandemic Response in the U.S.
1/11/2021
AMRI Included in BARDA CDMO Network in Support of COVID-19 Pandemic Response in the U.S.
-
TRI to Support BARDA's Clinical Studies Network
12/16/2020
Technical Resources International, Inc. (TRI) has been awarded the Clinical Studies Network (CSN) Clinical Trial Planning and Execution (CTPE) Contract in support of the Biomedical Advanced Research and Development Authority (BARDA), which is part of the U.S. Department of Health and Human Services (HHS) Office of the Assistant Sec
-
ImmunityBio’s hAd5 T-Cell COVID-19 Vaccine Candidate Shows Complete Protection of Airways in Non-Human Primates
12/11/2020
BARDA-sponsored study shows second-generation hAd5 vaccine candidate in both subcutaneous and room temperature oral formulations inhibits SARS-CoV-2 virus replication to undetectable levels and clears infection within days in 100% of vaccinated non-human primates
-
Moderna’s COVID-19 Vaccine Candidate Meets its Primary Efficacy Endpoint in the First Interim Analysis of the Phase 3 COVE Study
11/16/2020
Moderna intends to submit for an Emergency Use Authorization (EUA) with U.S. FDA in the coming weeks and expects the EUA to be based on the final analysis of 151 cases and a median follow-up of more than 2 months
-
Johnson & Johnson and U.S. Department of Health & Human Services Expand Agreement to Support Next Phase of COVID-19 Vaccine Candidate Research and Development
11/14/2020
Johnson & Johnson announced the expansion to the partnership between its Janssen Pharmaceutical Companies and the Biomedical Advanced Research and Development Authority, which is part of the Office of the Assistant Secretary for Preparedness and Response at the U.S. Department of Health and Human Services for the ongoing development of Janssen's investigational COVID-19 vaccine candidate.
-
Humanigen Announces Cooperative Research and Development Agreement with the Department of Defense to Develop Lenzilumab for COVID-19
11/6/2020
The Cooperative Research and Development Agreement (CRADA) with the Department of Defense (DoD) in support of Operation Warp Speed (OWS) aims to improve the availability of lenzilumab for patients with COVID-19 Humanigen’s development efforts complemented by full-scale, integrated team of OWS leading experts and U.S. Government decision makers dedicated to advancing lenzilumab ahead of a potential Emergency Use Authorization (EUA) submission
-
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for October 20, 2020.
-
BARDA reselects ICON as preferred partner to help strengthen US emergency preparedness and response
10/19/2020
ICON plc, (NASDAQ: ICLR) a global provider of outsourced drug and device development and commercialisation services to pharmaceutical, biotechnology, medical device industries and government and public health organisations, has been re-selected by the Biomedical Advanced Research and Development Authority (BARDA) to c
-
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for October 13, 2020.
-
In his resignation, Bright said that the Trump administration “ignores scientific expertise, overrules public health guidance and disrespects career scientists.”
-
Locus Biosciences signs contract with BARDA to advance $144 million precision medicine program to develop LBP-EC01, a crPhage™ product
9/30/2020
Locus Biosciences announced today that it has signed a contract with the Biomedical Advanced Research and Development Authority (BARDA) to co-fund development of LBP-EC01, a CRISPR Cas3-enhanced bacteriophage (crPhage™) product that will target Escherichia coli ( E. coli ) bacteria causing recurrent urinary tract infections
-
Esperovax Awarded New Contract With BARDA
9/23/2020
Esperovax, the leader in Egress RD™ Oral Biologics has been awarded $607,000 in funding from the Biomedical Advanced Research and Development Authority (BARDA), part of the Office of the Assistant Secretary for Preparedness and Respons
-
Luminex Receives BARDA Award to Support Enhancement of COVID-19 Multiplex Antibody Test
9/23/2020
Project will expand utility of xMAP SARS-CoV-2 Multi-Antigen IgG Assay to better indicate whether individuals are protected against future infection [23-September-2020] AUSTIN, Texas , Sept. 23, 2020 /PRNewswire/ -- Luminex Corporation (NASDAQ: LMNX) today announced that it has received an award of $683,500 from the Biomedical Advanced Research and Development Autho
-
Ortho Awarded BARDA Contract to Accelerate Antigen Test Development and Additional SARS-CoV-2 Antibody Test Milestones
9/21/2020
Ortho Clinical Diagnostics, a global leader of in vitro diagnostics, today announced its continued collaboration with the Biomedical Advanced Research and Development Authority ( BARDA ), part of the Office of the Assistant Secretary for Preparedness and Response at the U.S. Department of Health and Human Services, in a new contr